Search results
Health Care Roundup: Market Talk
The Wall Street Journal· 9 hours agoAstraZeneca, Sanofi and more in the latest Market Talks covering the Health Care sector.
Verdence Capital Advisors LLC Sells 3,751 Shares of Sanofi (NASDAQ:SNY)
ETF DAILY NEWS· 5 days agoVerdence Capital Advisors LLC lowered its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 20.3% in the fourth quarter, according to the company in its most recent ...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 4 days agoThat pursuit has a unique set of challenges and remains in its early stages. Many...Skyhawk has...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Morningstar· 4 days agoRilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 3 days agoIn March, AstraZeneca announced plans to acquire Fusion Pharmaceuticals FUSN, a Canadian company...
Kymera Therapeutics stock gets Outperform rating on positive outlook By Investing.com
Investing.com· 4 days agoOn Monday, Kymera Therapeutics shares (NASDAQ:KYMR) shares received a new Outperform rating from...
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings) - Biomarin...
Benzinga· 1 day agoPrice Targets: Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock...Biomarin Pharmaceutical BioMarin's focus is on rare-disease ...
U.S. Could Vaccinate a Fifth of Americans in a Bird Flu Emergency
Barrons.com· 7 days agoCSL Seqirus and GSK under contract with HHS, are testing vaccines targeting a strain of avian...
Endeavor pulls in $132M to back cancer, lung disease drugs
BioPharma Dive via Yahoo Finance· 3 days agoLed by the founder of a biotech Celgene acquired for $7 billion, the startup is developing two...
AstraZeneca encounters a surge in shares as profits exceed expectations, buoyed by demand for cancer...
Fortune· 1 day agoEarnings per share excluding some items rose 7% to $2.06 in the first quarter, the UK drugmaker said Thursday. Analysts surveyed by Bloomberg expected $1.89 on average. Astra has been on a deal ...